Cerecor Announces Positive Initial Phase 1b Results for CERC-002 in Moderate to Severe Crohn’s Disease PatientsJuly 26th, 2021|Cell and Gene Therapy, Innovation, Regional News Roundup|Comments Off on Cerecor Announces Positive Initial Phase 1b Results for CERC-002 in Moderate to Severe Crohn’s Disease Patients A biopharmaceutical company announced the results of a Phase 1b of CERC-002.Article from GlobeNewswireShare This Story, Choose Your PlatformFacebookTwitterLinkedInPinterestEmail Related Posts Stories From Our Region – August 2023 Stories From Our Region – July 2023 Greater Philadelphia’s Quality of Life Stars in the Chamber’s “Discovery Starts with Me” Video Series Stories From Our Region – June 2023 Stories From Our Region – May 2023